US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON

0.8411

-0.0289-3.32%

Post-market: 0.84110.00000.00%17:50 EDT

Volume:27.54K

Turnover:23.62K

Market Cap:33.93M

PE:-0.51

High:0.9317

Open:0.9240

Low:0.8250

Close:0.8700

Loading ...

Overview Company News Filings

European Equities Traded in the US as American Depositary Receipts Rise Wednesday

MT Newswires Live

Barinthus Biotherapeutics Q1 EPS $(0.49) Misses $(0.36) Estimate

Press Release: Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments

Barinthus Biotherapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.

Barinthus Biotherapeutics PLC reports results for the quarter ended December 31 - Earnings Summary

Barinthus Biotherapeutics Says As Of December 31, 2024 Cash, Cash Equivalents And Restricted Cash Was $112.4M That Is Expected To Provide Cash Runway Into 2027

Barinthus Biotherapeutics FY 2024 GAAP EPS $(1.55) Beats $(1.67) Estimate, Sales $14.97M Inline

Press Release: Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

Calendar of U.S. Earnings Expected in the Week Ahead

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

ACCESS Newswire

Barinthus Biotherapeutics PLC expected to post a loss of 41 cents a share - Earnings Preview

Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11

ACCESS Newswire

US Exchange Insights: 3 Penny Stocks With Over $40M Market Cap

Simply Wall St.

Barinthus Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.

Press Release: Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BRNS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BRNS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRNS\",,,,,undefined,":{"symbol":"BRNS","market":"US","secType":"STK","nameCN":"BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON","latestPrice":0.8411,"timestamp":1750449600000,"preClose":0.87,"halted":0,"volume":27543,"hourTrading":{"tag":"盘后","latestPrice":0.8411,"preClose":0.8411,"latestTime":"17:50 EDT","volume":48,"amount":39.8976,"timestamp":1750456228065},"delay":0,"floatShares":26230183,"shares":40339395,"eps":-1.642272,"marketStatus":"Market Closed","change":-0.0289,"latestTime":"06-20 16:00:00 EDT","open":0.924,"high":0.9317,"low":0.825,"amount":23618.386913,"amplitude":0.122644,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.642272,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750665600000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1619755200000,"exchange":"NASDAQ","adjPreClose":0.87,"postHourTrading":{"tag":"盘后","latestPrice":0.8411,"preClose":0.8411,"latestTime":"17:50 EDT","volume":48,"amount":39.8976,"timestamp":1750456228065},"volumeRatio":4.291947045033648},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRNS\",,,,,undefined,":{"symbol":"BRNS","floatShares":26230183,"roa":"-18.20%","roe":"-45.42%","lyrEps":-1.55214,"volumeRatio":4.291947045033648,"shares":40339395,"dividePrice":0,"high":0.9317,"amplitude":0.122644,"preClose":0.87,"low":0.825,"week52Low":0.64,"pbRate":"0.29","psRate":"2.27","week52High":1.58,"institutionHeld":0,"latestPrice":0.8411,"eps":-1.642272,"divideRate":0,"volume":27543,"delay":0,"ttmEps":-1.642272,"open":0.924,"prevYearClose":1.208,"prevWeekClose":0.9033,"prevMonthClose":1.08,"prevQuarterClose":0.9727,"fiveDayClose":0.9143,"twentyDayClose":0.8291,"sixtyDayClose":1.025},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BRNS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2542356405","title":"European Equities Traded in the US as American Depositary Receipts Rise Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2542356405","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542356405?lang=en_us&edition=fundamental","pubTime":"2025-06-11 23:19","pubTimestamp":1749655191,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were rising on Wednesday morning, up 0.5% to 1,497.69 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by pharmaceutical company Addex Therapeutics  and advertising company Criteo , which rose 5.1% and 2% respectively.They were followed by energy company Eni , up 1.4%.The decliners from continental Europe were led by biotech companies Abivax  and Evaxion , which fell 2.9% and 2% respectively.From the UK and Ireland, the gainers were led by biopharmaceutical company Verona Pharma  and biotech firm Bicycle Therapeutics , which gained 4.8% and 3.9% respectively.They were followed by biotech company Barinthus Biotherapeutics , which added 2%.The decliners from the UK and Ireland were led by biotech firms Akari Therapeutics  and Autolus Therapeutics , which dropped 3.5% and 3.2% respectively.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4201","E","AKTX","ADXN","CRTO","ABVX","BK4117","BK4007","BRNS","BCYC","BK4009","BK4539","EVAX","IE00BFMHRM44.USD","AUTL","BK4107","AFG","VRNA","BK4139"],"gpt_icon":0},{"id":"2533093314","title":"Barinthus Biotherapeutics Q1 EPS $(0.49) Misses $(0.36) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2533093314","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533093314?lang=en_us&edition=fundamental","pubTime":"2025-05-07 21:20","pubTimestamp":1746624019,"startTime":"0","endTime":"0","summary":"Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.36) by 36.11 percent. This is a 22.5 percent decrease over losses of $(0.40) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45252430/barinthus-biotherapeutics-q1-eps-0-49-misses-0-36-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS"],"gpt_icon":0},{"id":"2533845939","title":"Press Release: Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2533845939","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533845939?lang=en_us&edition=fundamental","pubTime":"2025-05-07 20:00","pubTimestamp":1746619200,"startTime":"0","endTime":"0","summary":"-- Highly differentiated immunotherapy for celiac disease  in the. clinic, with Phase 1 single ascending dose readout from AVALON expected. -- Initiation of VTP-1000 multiple ascending dose expected in the second. -- Encouraging results from HBV003 and IM-PROVE II presented at EASL,-- Available resources expected to provide a cash runway into 2027.OXFORD, United Kingdom and GERMANTOWN, Md., May 07, 2025  --  Barinthus Biotherapeutics plc  , an immunology and inflammation  company focused on developing therapies that promote immune tolerance with curative potential, today announced its financial results for the quarter ended March 31, 2025 and provided an overview of the Company's corporate developments.The HBV003 study is evaluating the safety, immunogenicity and disease modifying activity of three different dosing regimens of VTP-300 in combination with low-dose nivolumab , an anti-PD-1 monoclonal antibody. The primary analysis showed;","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BRNS"],"gpt_icon":0},{"id":"2521285794","title":"Barinthus Biotherapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2521285794","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521285794?lang=en_us&edition=fundamental","pubTime":"2025-03-21 20:31","pubTimestamp":1742560260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BRNS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 21, 2025 08:31 ET (12:31 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS"],"gpt_icon":0},{"id":"2520211454","title":"Barinthus Biotherapeutics PLC reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2520211454","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520211454?lang=en_us&edition=fundamental","pubTime":"2025-03-20 21:32","pubTimestamp":1742477523,"startTime":"0","endTime":"0","summary":"Barinthus Biotherapeutics PLC reports results for the quarter ended December 31 - Earnings SummaryBarinthus Biotherapeutics PLC BRNS.OQ reported a quarterly adjusted loss of 51 cents per share for the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nL8N3Q31E0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS"],"gpt_icon":0},{"id":"2520307934","title":"Barinthus Biotherapeutics Says As Of December 31, 2024 Cash, Cash Equivalents And Restricted Cash Was $112.4M That Is Expected To Provide Cash Runway Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2520307934","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520307934?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:28","pubTimestamp":1742470137,"startTime":"0","endTime":"0","summary":"Barinthus Biotherapeutics Says As Of December 31, 2024 Cash, Cash Equivalents And Restricted Cash Was $112.4M That Is Expected To Provide Cash Runway Into 2027","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/25/03/44413744/barinthus-biotherapeutics-says-as-of-december-31-2024-cash-cash-equivalents-and-restricted-cash-w","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS","BK4139"],"gpt_icon":0},{"id":"2520430784","title":"Barinthus Biotherapeutics FY 2024 GAAP EPS $(1.55) Beats $(1.67) Estimate, Sales $14.97M Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2520430784","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520430784?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:27","pubTimestamp":1742470042,"startTime":"0","endTime":"0","summary":"Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(1.55) per share which beat the analyst consensus estimate of $(1.67) by 7.19 percent. This is a 18.85 percent increase over losses of $(1.91) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44413738/barinthus-biotherapeutics-fy-2024-gaap-eps-1-55-beats-1-67-estimate-sales-14-97m-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Barinthus Biotherapeutics FY 2024 GAAP EPS $(1.55) Beats $(1.67) Estimate, Sales $14.97M Inline","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS"],"gpt_icon":0},{"id":"2520304904","title":"Press Release: Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2520304904","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520304904?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:22","pubTimestamp":1742469720,"startTime":"0","endTime":"0","summary":"-- Strategic transformation ongoing, positioning the Company as a focused. -- Highly differentiated, potentially curative immunotherapy for celiac. disease  in the clinic, with first data expected in third. \"Turning to our development candidates designated for partnering, we reported highly encouraging results from two Phase 2 trials in our chronic hepatitis B  program demonstrating that VTP-300 contributed to the achievement of undetectable HBsAg levels in eight participants, with two participants meeting functional cure criteria. Further Phase 2 data are anticipated in the second quarter of 2025, which are expected to strengthen VTP-300's market positioning as a component of a functional cu","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4022","R","BK4232","BRNS"],"gpt_icon":0},{"id":"2520439968","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2520439968","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520439968?lang=en_us&edition=fundamental","pubTime":"2025-03-20 18:00","pubTimestamp":1742464800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Amprius Tech Inc                                4Q      (.11)  4:05 PM. ·Lands' End Inc.                                   4Q       .57   6:45 AM. ·Lennar Corp Class A                              1Q      1.70       AMC","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKE","SKYE","MNSO","KLC","CMC","OUST","MBRX","BLRX","FLUX","IFRX","SBS","SPRY","COYA","CELC","MREO","TITN","BRAG","MLKN","PL","PAYX","BBNX","JKS","RLMD","WOR","GDEV","SOWG","TELA","LEN","FBRX","ASO","MGNX","LVTX","NKTX","ACRV","JEF","LPTX","TH","CURV","CDLR","THRD","CBUS","DRI","ALUR","BRNS","RUM","DERM","SLS","BCAB"],"gpt_icon":1},{"id":"2520931355","title":"Q1 Virtual Investor Summit: On-Demand Presentations Now Live","url":"https://stock-news.laohu8.com/highlight/detail?id=2520931355","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520931355?lang=en_us&edition=fundamental","pubTime":"2025-03-19 03:30","pubTimestamp":1742326200,"startTime":"0","endTime":"0","summary":"NEW YORK, NY / ACCESS Newswire / March 18, 2025 / The Investor Summit is excited to announce that presentations from Q1 Investor Summit are now available for on-demand viewing. Attendees and investors who missed the live sessions can now access company presentations at their convenience.The event, which took place on March 11, featured a diverse lineup of microcap companies showcasing their latest developments, growth plans, and market strategies. With on-demand access, you have the flexibility to revisit key insights and explore potential opportunities to revisit key insights shared during the event.Click the Company Names Below To Access Presentations:. 100% complete response rate  in the most recent U.S. trial results in skin cancer, led by Memorial Sloan Kettering Cancer Center in NY.RI/ROYIF's trifecta strategy combines the upside from the breakout of the silver price to $40-50 to monetize its silverasset for $5-10 million and a potential up to $25 million legal settlement on a co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q1-virtual-investor-summit-demand-193000244.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MRK","UAMY","SG9999015341.SGD","GIFT","ROYIF","LU1585245621.USD","LU1291159041.SGD","BK4230","LU1035773651.USD","TSYW.SI","LU0985320562.USD","IE00B4R5TH58.HKD","PSQ","TQQQ","LU1116320901.HKD","DRTSW","PYPD","PRPH","FEMY","VOXR","ZCAR","LU1983299246.USD","ZCARW","LU0211331839.USD","BRNS","SNANF","MNQmain","LU1066053197.SGD","NVIW.SI","SG9999014567.USD","SMMF","USJW.SI","LU1066051225.USD","PERF","USAW.SI","LU1037948897.HKD","IE00BLSP4239.USD","LU1069347547.HKD","DRTS","QLD","SG9999015358.SGD","LU1917777945.USD","LU2361044865.SGD","CLNN","SQQQ","CLNNW","MIND","TOVX","LU1934455194.USD","QID","IE00BLSP4452.SGD","NQmain",".IXIC","LU1929549753.HKD"],"gpt_icon":1},{"id":"2519804154","title":"Barinthus Biotherapeutics PLC  expected to post a loss of 41 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2519804154","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519804154?lang=en_us&edition=fundamental","pubTime":"2025-03-14 21:20","pubTimestamp":1741958406,"startTime":"0","endTime":"0","summary":"Barinthus Biotherapeutics PLC  expected to post a loss of41cents a share - Earnings Preview Barinthus Biotherapeutics PLC BRNS.OQ, BRNS.O is expected to show no change in quarterly revenue when it rep","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL8N3PX19L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS"],"gpt_icon":0},{"id":"2517577211","title":"Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11","url":"https://stock-news.laohu8.com/highlight/detail?id=2517577211","media":"ACCESS Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517577211?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:30","pubTimestamp":1741267800,"startTime":"0","endTime":"0","summary":"NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bill Enright, CEO and Gemma Brown, CFO of Barinthus Biotherapeutics plc, will be presenting at this year's Investor Summit Virtual on March 11th.About Barinthus Biotherapeutics plcBarinthus Biotherapeutics  is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates designed to guide the immune system to overcome autoimmunity and chronic infectious diseases. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Bio. With a focused pipeline built around its proprietary platform technologies, Barinthus Bio is advancing immunotherapeutic product candidates in autoimmunity and infectious diseases, including: VTP-1000, utilizing the SNAP-Tolerance Immunotherapy  platform designed to treat people with celiac disease and VTP-300, that is utilizing the ChAdOx/MVA platform designed as a potential component of a functional cure for chronic HBV infection Fur","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/barinthus-biotherapeutics-plc-present-investor-133000766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","BK4139","SMMF","BRNS"],"gpt_icon":0},{"id":"2508683120","title":"US Exchange Insights: 3 Penny Stocks With Over $40M Market Cap","url":"https://stock-news.laohu8.com/highlight/detail?id=2508683120","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508683120?lang=en_us&edition=fundamental","pubTime":"2025-02-04 04:05","pubTimestamp":1738613109,"startTime":"0","endTime":"0","summary":"As the U.S. stock market navigates a landscape marked by tariff uncertainties and fluctuating indices, investors are keenly observing opportunities that may arise in less conventional areas of the market. Penny stocks, while often associated with higher risk, continue to capture attention due to their potential for significant returns when backed by solid fundamentals. In this article, we explore three penny stocks that exhibit financial stability and growth potential, offering investors a chance to uncover value beyond traditional blue-chip investments.Overview: CBAK Energy Technology, Inc. is involved in the manufacturing, commercialization, and distribution of lithium-ion high power rechargeable batteries across Mainland China, the United States, Europe, and other international markets with a market cap of $85.11 million.Click here to discover the nuances of CBAK Energy Technology with our detailed analytical financial health report.Gain insights into CBAK Energy Technology's future","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/us-exchange-insights-3-penny-200509794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4096","IMPPP","BABB","BRNS","BK4213","CBAT","PVL","IMPP","NRT","BK4209"],"gpt_icon":0},{"id":"2503530309","title":"Barinthus Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2503530309","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503530309?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:20","pubTimestamp":1736770800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BRNS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2025 07:20 ET (12:20 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS"],"gpt_icon":0},{"id":"2502686810","title":"Press Release: Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2502686810","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502686810?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514000,"startTime":"0","endTime":"0","summary":"Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update. -- Prioritizing VTP-1000 development in celiac disease, Phase 1 data. -- Postponing further clinical development of VTP-300 in chronic hepatitis B. -- Extending the cash runway to the start of 2027 by reducing costs,including an approximate 65% reduction in workforce and expected closure. -- Future operations will be focused at the U.S. site in Germantown,OXFORD, United Kingdom and GERMANTOWN, Md., Jan. 10, 2025  -- Barinthus Biotherapeutics plc  , today provided a strategic business and financial update. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease.-- The Company will prioritize I&I indications, including antigen-specific. -- The Company plans to extend the cash runway to the start of 2027 by. reducing costs, including a reduction in headcount by approximately 65%. across both si","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSA","BK4217","BK4588","CHB","BRNS","BK4139","BK4585","BK4533","BK4084"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BRNS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-07","symbol":"BRNS","fiscalQuarterEnding":"2025/03","expectedEps":-0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":-0.49},{"market":"US","date":"2025-03-20","symbol":"BRNS","fiscalQuarterEnding":"2024/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"pre","actualEps":-0.51},{"market":"US","date":"2024-11-06","symbol":"BRNS","fiscalQuarterEnding":"2024/09","expectedEps":-0.45,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730869200000,"reportTimeType":"pre","actualEps":-0.21},{"market":"US","date":"2024-08-08","symbol":"BRNS","fiscalQuarterEnding":"2024/06","expectedEps":-0.42,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"pre","actualEps":-0.43},{"market":"US","date":"2024-05-13","symbol":"BRNS","fiscalQuarterEnding":"2024/03","expectedEps":-0.64,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715572800000,"reportTimeType":"pre","actualEps":-0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BRNS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BRNS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1701316800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BRNS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BRNS","date":"2025-06-20","current":-0.537999,"percent":0.939633,"low":-2.280697,"twenty":-1.347036,"median":-0.790952,"eighty":-0.674799,"high":-0.404427,"avg":-0.978004,"sd":0.379749,"marketCap":35095273},"quantilePoints":[{"date":"2023-11-10","current":-2.280697,"twenty":-2.227364,"median":-2.147364,"eighty":-2.067364,"marketCap":125276430},{"date":"2023-11-17","current":-1.472853,"twenty":-1.912639,"median":-1.482838,"eighty":-1.444894,"marketCap":113767552},{"date":"2023-11-22","current":-1.35802,"twenty":-1.608463,"median":-1.465364,"eighty":-1.380987,"marketCap":104897539},{"date":"2023-12-01","current":-1.425372,"twenty":-1.531387,"median":-1.472853,"eighty":-1.406949,"marketCap":110099995},{"date":"2023-12-08","current":-1.545247,"twenty":-1.548243,"median":-1.492824,"eighty":-1.422886,"marketCap":119359516},{"date":"2023-12-15","current":-1.502809,"twenty":-1.545746,"median":-1.507071,"eighty":-1.435398,"marketCap":116081468},{"date":"2023-12-22","current":-1.667569,"twenty":-1.629624,"median":-1.518886,"eighty":-1.45388,"marketCap":128808008},{"date":"2023-12-29","current":-1.818598,"twenty":-1.661578,"median":-1.524178,"eighty":-1.463866,"marketCap":140474003},{"date":"2024-01-05","current":-1.822343,"twenty":-1.722489,"median":-1.530269,"eighty":-1.472853,"marketCap":140763242},{"date":"2024-01-12","current":-1.657583,"twenty":-1.757438,"median":-1.547743,"eighty":-1.472853,"marketCap":128036703},{"date":"2024-01-19","current":-1.647598,"twenty":-1.741461,"median":-1.572707,"eighty":-1.480841,"marketCap":127265397},{"date":"2024-01-26","current":-1.452882,"twenty":-1.725485,"median":-1.553984,"eighty":-1.480841,"marketCap":112224941},{"date":"2024-02-02","current":-1.352528,"twenty":-1.722489,"median":-1.532765,"eighty":-1.451873,"marketCap":104473321},{"date":"2024-02-09","current":-1.271197,"twenty":-1.706512,"median":-1.523479,"eighty":-1.406949,"marketCap":98191039},{"date":"2024-02-16","current":-1.238844,"twenty":-1.682547,"median":-1.517787,"eighty":-1.357411,"marketCap":95692009},{"date":"2024-02-23","current":-1.338049,"twenty":-1.677554,"median":-1.516789,"eighty":-1.341045,"marketCap":103354928},{"date":"2024-03-01","current":-1.41294,"twenty":-1.674558,"median":-1.50494,"eighty":-1.343042,"marketCap":109139719},{"date":"2024-03-08","current":-1.323071,"twenty":-1.669566,"median":-1.502809,"eighty":-1.343042,"marketCap":102197970},{"date":"2024-03-15","current":-1.253173,"twenty":-1.661577,"median":-1.472853,"eighty":-1.328064,"marketCap":96798832},{"date":"2024-03-22","current":-1.269731,"twenty":-1.654588,"median":-1.472853,"eighty":-1.301103,"marketCap":93130931},{"date":"2024-03-28","current":-1.236403,"twenty":-1.650594,"median":-1.452882,"eighty":-1.295112,"marketCap":90686423},{"date":"2024-04-05","current":-1.947467,"twenty":-1.650594,"median":-1.45036,"eighty":-1.291729,"marketCap":142840848},{"date":"2024-04-12","current":-1.767048,"twenty":-1.675557,"median":-1.472853,"eighty":-1.295112,"marketCap":129607635},{"date":"2024-04-19","current":-1.438048,"twenty":-1.670564,"median":-1.455378,"eighty":-1.298107,"marketCap":105476484},{"date":"2024-04-26","current":-1.288883,"twenty":-1.667031,"median":-1.438048,"eighty":-1.298107,"marketCap":94535731},{"date":"2024-05-03","current":-1.138233,"twenty":-1.662768,"median":-1.419156,"eighty":-1.291729,"marketCap":83485999},{"date":"2024-05-10","current":-1.247016,"twenty":-1.655586,"median":-1.407947,"eighty":-1.280564,"marketCap":91464848},{"date":"2024-05-17","current":-1.338523,"twenty":-1.650594,"median":-1.395374,"eighty":-1.278423,"marketCap":94574653},{"date":"2024-05-24","current":-1.248513,"twenty":-1.643604,"median":-1.379677,"eighty":-1.275322,"marketCap":88214937},{"date":"2024-05-31","current":-1.104879,"twenty":-1.635615,"median":-1.37437,"eighty":-1.270728,"marketCap":78066316},{"date":"2024-06-07","current":-1.046873,"twenty":-1.621636,"median":-1.366121,"eighty":-1.261117,"marketCap":73967834},{"date":"2024-06-14","current":-1.055159,"twenty":-1.597671,"median":-1.356497,"eighty":-1.253173,"marketCap":74553331},{"date":"2024-06-21","current":-0.690549,"twenty":-1.5777,"median":-1.352836,"eighty":-1.245382,"marketCap":48791447},{"date":"2024-06-28","current":-0.765129,"twenty":-1.570211,"median":-1.350281,"eighty":-1.236891,"marketCap":54060923},{"date":"2024-07-05","current":-0.789988,"twenty":-1.560225,"median":-1.343042,"eighty":-1.220891,"marketCap":55817415},{"date":"2024-07-12","current":-0.812086,"twenty":-1.547743,"median":-1.338523,"eighty":-1.203246,"marketCap":57378742},{"date":"2024-07-15","current":-0.834183,"twenty":-1.547244,"median":-1.338286,"eighty":-1.19142,"marketCap":58940068},{"date":"2024-08-02","current":-0.841641,"twenty":-1.546745,"median":-1.338049,"eighty":-1.17902,"marketCap":59467016},{"date":"2024-08-09","current":-0.844428,"twenty":-1.544819,"median":-1.331919,"eighty":-1.144779,"marketCap":53861854},{"date":"2024-08-16","current":-0.803496,"twenty":-1.539612,"median":-1.328064,"eighty":-1.092435,"marketCap":51250963},{"date":"2024-08-23","current":-0.772414,"twenty":-1.530768,"median":-1.322286,"eighty":-1.051845,"marketCap":49268402},{"date":"2024-08-30","current":-0.790952,"twenty":-1.527773,"median":-1.3031,"eighty":-1.045215,"marketCap":50450844},{"date":"2024-09-06","current":-0.760055,"twenty":-1.527054,"median":-1.298107,"eighty":-0.902686,"marketCap":48480108},{"date":"2024-09-13","current":-0.790952,"twenty":-1.523898,"median":-1.293812,"eighty":-0.829258,"marketCap":50450844},{"date":"2024-09-20","current":-0.756965,"twenty":-1.522221,"median":-1.290805,"eighty":-0.813197,"marketCap":48283034},{"date":"2024-09-27","current":-0.741517,"twenty":-1.519545,"median":-1.287184,"eighty":-0.79711,"marketCap":47297666},{"date":"2024-10-04","current":-0.766234,"twenty":-1.517727,"median":-1.278854,"eighty":-0.791312,"marketCap":48874255},{"date":"2024-10-11","current":-0.735276,"twenty":-1.517348,"median":-1.275766,"eighty":-0.790181,"marketCap":46899577},{"date":"2024-10-18","current":-0.741517,"twenty":-1.51599,"median":-1.271197,"eighty":-0.788177,"marketCap":47297666},{"date":"2024-10-25","current":-0.883641,"twenty":-1.511649,"median":-1.26959,"eighty":-0.788177,"marketCap":56363052},{"date":"2024-10-31","current":-0.883641,"twenty":-1.507071,"median":-1.261798,"eighty":-0.789436,"marketCap":56363052},{"date":"2024-11-08","current":-1.00297,"twenty":-1.502809,"median":-1.253173,"eighty":-0.789988,"marketCap":57998763},{"date":"2024-11-15","current":-0.960023,"twenty":-1.502809,"median":-1.24843,"eighty":-0.789988,"marketCap":55515269},{"date":"2024-11-22","current":-0.687502,"twenty":-1.482838,"median":-1.238844,"eighty":-0.784772,"marketCap":39756173},{"date":"2024-11-29","current":-0.685791,"twenty":-1.47485,"median":-1.235499,"eighty":-0.783536,"marketCap":39657211},{"date":"2024-12-06","current":-0.646972,"twenty":-1.472853,"median":-1.217885,"eighty":-0.773215,"marketCap":37412464},{"date":"2024-12-13","current":-0.570449,"twenty":-1.472853,"median":-1.204564,"eighty":-0.772414,"marketCap":32987333},{"date":"2024-12-20","current":-0.709582,"twenty":-1.472853,"median":-1.180594,"eighty":-0.767891,"marketCap":41033025},{"date":"2024-12-27","current":-0.737409,"twenty":-1.463866,"median":-1.162113,"eighty":-0.767891,"marketCap":42642163},{"date":"2025-01-03","current":-0.86263,"twenty":-1.455877,"median":-1.146416,"eighty":-0.766897,"marketCap":49883285},{"date":"2025-01-10","current":-0.793063,"twenty":-1.451873,"median":-1.104879,"eighty":-0.767891,"marketCap":45860439},{"date":"2025-01-17","current":-0.702626,"twenty":-1.445881,"median":-1.087822,"eighty":-0.76515,"marketCap":40630740},{"date":"2025-01-24","current":-0.751323,"twenty":-1.438048,"median":-1.055159,"eighty":-0.760055,"marketCap":43446732},{"date":"2025-01-31","current":-0.695669,"twenty":-1.437904,"median":-1.049635,"eighty":-0.751323,"marketCap":40228456},{"date":"2025-02-07","current":-0.695669,"twenty":-1.425372,"median":-1.046873,"eighty":-0.741517,"marketCap":40228456},{"date":"2025-02-14","current":-0.719983,"twenty":-1.41294,"median":-1.010409,"eighty":-0.741517,"marketCap":41634440},{"date":"2025-02-21","current":-0.733931,"twenty":-1.41294,"median":-0.988453,"eighty":-0.741517,"marketCap":42441021},{"date":"2025-02-28","current":-0.674799,"twenty":-1.408946,"median":-0.960023,"eighty":-0.737409,"marketCap":39021602},{"date":"2025-03-07","current":-0.709513,"twenty":-1.403161,"median":-0.92717,"eighty":-0.735338,"marketCap":41029002},{"date":"2025-03-14","current":-0.737409,"twenty":-1.400759,"median":-0.908358,"eighty":-0.735007,"marketCap":42642163},{"date":"2025-03-21","current":-0.665373,"twenty":-1.392324,"median":-0.894425,"eighty":-0.729208,"marketCap":40637009},{"date":"2025-03-28","current":-0.693525,"twenty":-1.384445,"median":-0.883641,"eighty":-0.723496,"marketCap":42356364},{"date":"2025-04-04","current":-0.50198,"twenty":-1.380338,"median":-0.866957,"eighty":-0.719294,"marketCap":30657940},{"date":"2025-04-11","current":-0.452443,"twenty":-1.378328,"median":-0.844428,"eighty":-0.715148,"marketCap":27632485},{"date":"2025-04-17","current":-0.465653,"twenty":-1.375818,"median":-0.840368,"eighty":-0.709554,"marketCap":28439273},{"date":"2025-04-25","current":-0.538968,"twenty":-1.373547,"median":-0.828027,"eighty":-0.702626,"marketCap":32916946},{"date":"2025-05-02","current":-0.719945,"twenty":-1.372998,"median":-0.823996,"eighty":-0.701628,"marketCap":43969940},{"date":"2025-05-09","current":-0.55655,"twenty":-1.364746,"median":-0.819794,"eighty":-0.695669,"marketCap":36305455},{"date":"2025-05-16","current":-0.537906,"twenty":-1.35851,"median":-0.812579,"eighty":-0.692991,"marketCap":35089222},{"date":"2025-05-23","current":-0.500895,"twenty":-1.356192,"median":-0.807791,"eighty":-0.687124,"marketCap":32674909},{"date":"2025-05-30","current":-0.680228,"twenty":-1.354242,"median":-0.797766,"eighty":-0.685478,"marketCap":44373334},{"date":"2025-06-06","current":-0.612205,"twenty":-1.352898,"median":-0.794041,"eighty":-0.680263,"marketCap":39936001},{"date":"2025-06-13","current":-0.565393,"twenty":-1.350731,"median":-0.792907,"eighty":-0.675893,"marketCap":36882308},{"date":"2025-06-20","current":-0.537999,"twenty":-1.347036,"median":-0.790952,"eighty":-0.674799,"marketCap":35095273}],"updateTime":1750601475870}}}